Recent Work
-
Without Reform, Medicare Policies Will Hamstring New Gene Therapies
It took until the fall of 2020 for Medicare to consistently pay an adequate amount for CAR-T therapy. Now that same agonizing process awaits a raft of promising gene therapies in the pipeline – with lives in the balance – unless policymakers take action.
Categorized in